Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed MM
NCT02204241Phase 2Completed
- Start
- Jun 2014
- Primary completion
- Jun 2015
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM). Primary endpoint: Dose Limiting Toxicity at 1 year. Started Jun 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02204241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204241.